Australian Tech Entrepreneur Used AI on Dog Vaccine
A Sydney-based tech founder uses AI to design a bespoke cancer vaccine for his dog, Rosie, signaling a new frontier i...
Biotech
Biotech insights await. This page curates 5 articles on Tempus, Moderna, Praxis, ImmunityBio and market moves to help you evaluate stocks and sharpen your portfolio strategy.
88 articlesBest Biotech Stocks Right Now: Growth Leaders to Watch
Biotech stocks rally as late-stage trial data and regulatory milestones boost investor confidence. Analysts say the b...
Biotech Stock 685% Draws Big Investment Amid FDA Filings
A biotech stock that sprinted 685% in months drew a sizeable institutional bet as it pressed ahead with two FDA filin...
Mineralys (MLYS) 2025 Earnings: A Practical Investor Guide
What Mineralys (MLYS) reported in its 2025 earnings reveals more than numbers. This guide breaks down the quarter, th...
Lantheus Holdings Stock Popped Last Month: Key Drivers
An almost 12% jump in lantheus holdings stock popped last month left investors asking what lit the fuse. This article...
This Biotech’s Stock Soaring After FDA Official Exits
Biotech stocks surged after news that a polarizing FDA official is stepping down. The rally centers on this biotech’s...
This Next-Gen Obesity Drug: Can It Save Novo Nordisk?
Novo Nordisk faces intense pressure in the fast-growing obesity treatment space. This article dives into whether this...
MediWound (MDWD) 2025 Earnings: A Comprehensive Look
As 2025 unfolds, MediWound faces a pivotal year for debt, cash, and milestones. This analysis breaks down what mediwo...
Biotech Giants 2026: Top Stocks to Buy for Growth and Safety
Biotech giants 2026 could offer a compelling mix of growth and stability for investors. This article dives into two p...
Pulmonx (Lung) 2025 Earnings Outlook for Investors
Pulmonx is navigating a pivotal year as it advances its lung care devices while contending with pacing competition an...
Forget This Biotech Stock’s Rally Signals Fresh Jump
NovaGen Therapeutics rockets after a major AI-driven deal, highlighting a rare biotech upside amid a cooling AI market.
Forget Crispr Therapeutics: This Gene-Editing Pick Attracts
The gene-editing field is maturing from hype to real profits. This article outlines why a broader set of players coul...